RMD רווח נקי למניה (EPS TTM) ResMed Corporation

ResMed Inc. leverages its leadership in apnea therapy and rising demand driven by the obesity epidemic. The annual net income per share trend confirms the resilience of the model, where 10.97 characterizes this valuation parameter. The brand's impeccable authority among physicians and the stabilization of electronics supply chains guarantee the company seamless global shipments of high-tech devices.

Under the leadership of Mick Farrell, ResMed Inc. dominates the sleep apnea therapy segment by integrating digital innovations into its business structure. The eps_ttm_co metric reflects the actual per-share income for the year, excluding the impact of share issuance, which allows investors to determine the true pace of capitalization through the current rolling earnings per share and avoid the risks of purchasing the asset at a local peak.